International Consensus Redefines Cancer Trial Metrics to Prioritize Patient Longevity and Reduced Treatment Burden

Global experts led by MedUni Vienna introduce new metrics for cancer trials, focusing on patient quality of life and delaying systemic therapy changes.

By: AXL Media

Published: Apr 29, 2026, 4:18 AM EDT

Source: Information for this report was sourced from EurekAlert!

A Transformative Shift in Evaluating Metastatic Cancer Care

Medical researchers have unveiled a new framework for clinical trials that fundamentally alters how the efficacy of cancer treatments is measured for patients with isolated metastases. According to Joachim Widder of the Department of Radiation Oncology at MedUni Vienna, the traditional reliance on progression-free survival has often failed to capture the unique advantages provided by local, high-precision interventions. The new consensus aims to move beyond broad survival statistics to include metrics that are more directly aligned with the lived experience of patients, such as the duration of time spent without the need for aggressive systemic drug therapies.

Standardizing Success in the Oligometastatic Frontier

Oligometastatic disease occupies a critical middle ground between a localized tumor and widespread, advanced metastasis, representing a stage where a cure or long-term management remains possible. The newly published standards are a product of OligoCare, a massive prospective study involving over 3,500 patients that evaluates stereotactic ablative radiotherapy across various tumor types. By focusing on this specific disease stage, the consortium of experts from EORTC and ESTRO sought to define primary study endpoints that remain valid and applicable regardless of the primary cancer type, provided the disease has not yet reached a polymetastatic state.

Introducing Metrics for Systemic Therapy Delays

At the heart of this paradigm shift are two newly defined metrics: STFS and pPFS. The first, Start or Switch of Systemic Therapy–Free Survival, measures the interval before a patient must begin or change their medication regimen, effectively tracking "treatment-free" time. The second, polymetastatic Progression–Free Survival, monitors the duration until the cancer transitions into a more dangerous, widespread stage. These endpoints acknowledge that metastasis-directed therapies, such as surgical resection or thermal ablation, allow for repeated and targeted removal of individual growths, which traditional metrics often penalized as "progression" even if the overall disease remained controlled.